Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Immunol. 2016 Feb 1;196(5):2181–2194. doi: 10.4049/jimmunol.1500303

FIGURE 4.

FIGURE 4

A, CGRP pretreatment of pDMECs induces T cells with increased levels of mRNA for IL-17A and IL-6 accompanied by decreased levels of mRNA for IFNγ, IL-22 and IL-4. pDMECs pretreated with CGRP or medium alone were added to cultures of LCs and CD4+ T cells from DO11.10 Tg mice. Twenty-four hours later, LCs still bound to beads were moved by magnetic capture and total RNA was isolated from the remaining cells. By RT-PCR cultures containing medium-treated pDMECs had significantly increased IL-17A, IL-6, IFNγ and IL-22 levels while a small and not significant decrease in the IL-4 mRNA level was observed. Addition of CGRP-treated pDMECs led to a substantial and significant further increase in IL-17A and IL-6 mRNA levels accompanied by loss of the increase in IFNγ and IL-22 mRNA seen with addition of medium-treated pDMECs. The level of IL-4 was further decreased compared to wells containing medium-treated pDMECs with a p value of 0.07. B, CGRP pretreated pDMECs lead to enhanced mRNA levels of RORγT accompanied by decreased levels of T-bet and GATA3. Addition of medium-treated pDMECs led to a small but significant decrease in GATA3 mRNA levels. Addition of CGRP-treated pDMECs resulted in a large increase in the level of RORγt mRNA, the loss of the increase in T-bet observed, and a further small but significant decrease in the level of GATA3 mRNA compared to wells containing medium-treated pDMECs. n=6 experiments for all except T-bet which was 7. *p < 0.05, **p < 0.01, *** p < 0.001.